Management of Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Antiretroviral (ARV) Combination Therapy Including Raltegravir (MK-0518-138)

Collection of Data on the Management of HIV-1 Patients Treated With Antiretroviral Combination Therapy Including the HIV Integrase Inhibitor Raltegravir

To evaluate the management of HIV-1 participants treated with antiretroviral combination therapy including the integrase inhibitor raltegravir, all across the country of France.

Inclusion Criteria:

• Participant Infected With HIV-1.
• Participant for whom raltegravir therapy has been decided and started less than 30 days prior to inclusion in the study.
• Participant who has received oral and written information about the study and who has agreed to the computer processing of his/her personal data.

Exclusion Criteria:

• Participant taking part in a clinical trial to assess raltegravir.
• Participant in whom raltegravir treatment was started more than 30 days ago.